SynthesisFrontiers in oncology2022

Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review.

Chuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.